Hikma Pharmaceuticals USA INC.
Pharmaceutical manufacturer
Based in NJ
🤖
AI Overview
With $570K in lobbying spend across 17 quarterly filings, Hikma Pharmaceuticals USA INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2022 to 2025.
$570K
Total Spend
4
Years Active
1
Firms Hired
3
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2022 | $100K |
| 2023 | $200K |
| 2024 | $110K |
| 2025 | $160K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Trade
- •Health and pharmaceutical policies before the Congress and the Administration
- •Health and pharmaceutical policies before the Congress and the Administration. S. 3799, Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act, all provisions related to
- •Health and pharmaceutical policies before the Congress. S. 4348, FDASLA Act of 2022, all provisions related to fees related to generic drugs.
- •Health and pharmaceutical policies and domestic pharmaceutical manufacturing supply chain issues before the Congress.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.